Neuropathy, Neuromuscular disease, Multifocal motorneuropathy
ARGXArgenxCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Empasiprubart in Neuropathy, Neuromuscular disease, Multifocal motorneuropathy . The expected timing is based on the latest available company guidance and may change.
EMPASSION trial. 6/25/24 Top-line results from 1st cohort at PNS '24. Reports data from 2nd cohort later in 2024. 10/15/24 Presentation at AANEM '24. Initiate Ph3 in Q4 '24. 2/27/25- Topline data in H2 2026. 01/12/26:- EMPASSION MMN Phase 3 topline results now guided for Q4 2026.
Verification
Confirm timing and program details against the company announcement or filing.